The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19

References

• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Sharma A, Tiwari S, Deb MK, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054. doi: 10.1016/j.ijantimicag.2020.106054
   PubMed Web of Science ®Google Scholar
• Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–12. doi: 10.1016/j.jmii.2020.02.012
   PubMedGoogle Scholar
• Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95(6):e28869. doi: 10.1002/jmv.28869
   PubMed Web of Science ®Google Scholar
• Nagy É, Cseh V, Barcs I, et al. The impact of comorbidities and obesity on the severity and outcome of COVID-19 in hospitalized patients—A retrospective study in a Hungarian hospital. Int J Environ Res Public Health. 2023;20(2):1372. doi: 10.3390/ijerph20021372
   PubMed Web of Science ®Google Scholar
• Kruglikov IL, Shah M, Scherer PE. Obesity and diabetes as comorbidities for COVID-19: underlying mechanisms and the role of viral-bacterial interactions. Elife. 2020;9. doi: 10.7554/eLife.61330
   PubMed Web of Science ®Google Scholar
• Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29(2):334–343. doi: 10.1038/s41591-022-02156-9
   PubMed Web of Science ®Google Scholar
• Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls. Treasure island (FL) ineligible companies. Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC; 2023.
   Google Scholar
• Golubnitschaja O, Liskova A, Koklesova L, et al. Caution, “normal” BMI: health risks associated with potentially masked individual underweight—EPMA position paper 2021. EPMA J. 2021;12(3):243–264. doi: 10.1007/s13167-021-00251-4
   PubMed Web of Science ®Google Scholar
• Dobner J, Kaser S. Body mass index and the risk of infection - from underweight to obesity. Clin Microbiol Infect. 2018;24(1):24–28. doi: 10.1016/j.cmi.2017.02.013
   PubMed Web of Science ®Google Scholar
• Harpsøe MC, Nielsen NM, Friis-Møller N, et al. Body mass index and risk of infections among women in the Danish national birth cohort. Am J Epidemiol. 2016;183(11):1008–1017. doi: 10.1093/aje/kwv300
   PubMed Web of Science ®Google Scholar
• Phung DT, Wang Z, Rutherford S, et al. Body mass index and risk of pneumonia: a systematic review and meta-analysis. Obes Rev. 2013;14(10):839–857. doi: 10.1111/obr.12055
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou X, Wang M, et al. The impact of SARS-CoV-2 on the human immune system and microbiome. Infec Microbes Dis. 2021;3(1):14. doi: 10.1097/IM9.0000000000000045
   Google Scholar
• Shah VK, Firmal P, Alam A, et al. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11:1949. doi: 10.3389/fimmu.2020.01949
   PubMed Web of Science ®Google Scholar
• Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol. 2016;37(6):386–398. doi: 10.1016/j.it.2016.04.003
   PubMed Web of Science ®Google Scholar
• Calder PC. Nutrition and immunity: lessons for COVID-19. Nut Diabetes. 2021;11(1):19. doi: 10.1038/s41387-021-00165-0
   Google Scholar
• Guglielmi V, Colangeli L, D’Adamo M, et al. Susceptibility and severity of viral infections in obesity: lessons from influenza to COVID-19. Does leptin play a role? Int J Mol Sci. 2021;22(6):3183. doi: 10.3390/ijms22063183
   PubMed Web of Science ®Google Scholar
• James PT, Ali Z, Armitage AE, et al. The role of nutrition in COVID-19 susceptibility and severity of disease: a systematic review. J Nutr. 2021;151(7):1854–78. doi: 10.1093/jn/nxab059
   PubMed Web of Science ®Google Scholar
• Silverio R, Gonçalves DC, Andrade MF, et al. Coronavirus disease 2019 (COVID-19) and nutritional status: the missing link? Adv Nutr. 2021;12(3):682–692. doi: 10.1093/advances/nmaa125
   PubMed Web of Science ®Google Scholar
• Foolchand A, Ghazi T, Chuturgoon AA. Malnutrition and dietary habits alter the immune system which may consequently influence SARS-CoV-2 virulence: a review. Int J Mol Sci. 2022;23(5):23. doi: 10.3390/ijms23052654
   Web of Science ®Google Scholar
• Ye P, Pang R, Li L, et al. Both underweight and obesity are associated with an increased risk of coronavirus disease 2019 (COVID-19) severity. Front Nutr. 2021;8:649422. doi: 10.3389/fnut.2021.649422
   PubMed Web of Science ®Google Scholar
• Chen YC, Ho CH, Liu TH, et al. Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol. 2023;95(4):e28745. doi: 10.1002/jmv.28745
   PubMed Web of Science ®Google Scholar
• Chuang MH, Wu JY, Liu TH, et al. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J Med Virol. 2023;95(4):e28750. doi: 10.1002/jmv.28750
   PubMed Web of Science ®Google Scholar
• TriNetX. TriNetX Publication Guidelines.
   Google Scholar
• Hsu WH, Tsai YW, Wu JY, et al. Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors. J Infect. 2023;86:e107–e110. doi: 10.1016/j.jinf.2023.02.007
   PubMed Web of Science ®Google Scholar
• Chang YH, Liu TH, Wu JY, et al. The association between corticosteroids and aspergillosis among COVID-19 patients. J Infect. 2023;86(4):394–396. doi: 10.1016/j.jinf.2023.01.034
   PubMed Web of Science ®Google Scholar
• Wu JY, Liu MY, Liu TH, et al. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. J Med Virol. 2023;95(6):e28866. doi: 10.1002/jmv.28866
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638. doi: 10.1001/jama.2015.13480
   PubMed Web of Science ®Google Scholar
• Espiritu AI, Reyes NGD, Leochico CFD, et al. Body mass index and its association with COVID-19 clinical outcomes: findings from the Philippine CORONA study. Clin Nutr ESPEN. 2022;49:402–410. doi: 10.1016/j.clnesp.2022.03.013
   PubMed Web of Science ®Google Scholar
• Kananen L, Eriksdotter M, Boström AM, et al. Body mass index and mini nutritional assessment-short form as predictors of in-geriatric hospital mortality in older adults with COVID-19. Clin Nutr. 2022;41(12):2973–2979. doi: 10.1016/j.clnu.2021.07.025
   PubMed Web of Science ®Google Scholar
• Bouziotis J, Arvanitakis M, Preiser JC. Association of body mass index with COVID-19 related in-hospital death. Clin Nutr. 2022;41(12):2924–2926. doi: 10.1016/j.clnu.2022.01.017
   PubMedGoogle Scholar
• Kim TS, Roslin M, Wang JJ, et al. BMI as a risk factor for clinical outcomes in patients hospitalized with COVID-19 in New York. Obesity (Silver Spring). 2021;29:279–284. doi: 10.1002/oby.23076
   PubMedGoogle Scholar
• Liu TH, Huang PY, Wu JY, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data. J Med Virol. 2023;95(5):e28801. doi: 10.1002/jmv.28801
   PubMed Web of Science ®Google Scholar
• Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. Ann Intern Med. 2023;176:807–816. doi: 10.7326/M22-3565
   PubMed Web of Science ®Google Scholar
• Wee LE, Tay AT, Chiew C, et al. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during omicron BA.2, BA.4/5 and XBB transmission. Clin Microbiol Infect. 2023;29:1328–1333. doi: 10.1016/j.cmi.2023.06.016
   PubMed Web of Science ®Google Scholar